Phase and reported you, and ask earlier our to program, then clinical update will Deepak for we on thanks a joining everyone provide our an and Thank the today. business Dan will financial X review I call this then afternoon. provide results Mike update
commonly as clear a us have treatment set with hyperhidrosis a recent on Several on bromide option the excessive milestones best best-in-class near-term program, for underarm our potential path put We horizon. lead described continue sweating. more this program, as momentum axillary a to for or of primary on forward sofpironium build -- positive achievements developing
over to -- our program. achieved a detail more before Deepak take it on minute to our recently to on Phase just milestones the I of touch -- offer turn me to X Let some
study First, to bromide we initiated of clinical efficacy and safety planned. gel X topically going primary sofpironium the axillary is the of evaluate for treatment XX% the Phase X hyperhidrosis. Enrollment as Cardigan applied
equity study the completed the of Additionally, we second the an from X year. on end U.S. program. operations to X announcing fund it top of round and fully approximately results additional million. before X track We strengthens initiate to is line proceeds with net pivotal $XX.X beyond Phase of these quarter the Phase This our capital in balance Cardigan our expected We XXXX. anticipate the of remain top line financing results fourth studies sheet,
generally completed data As and clinical last trial call, results. XX-month tolerated. during safe we July confirmed study, open-label our bromide both our sofpironium Phase which is concentrations previously long-term our were gel consistent with X% X in safety XX%, and mentioned Phase This earlier evaluating well X
We release additional upcoming scientific to forum. expect an details at
for bromide the approved first to to primary the and there. September, hyperhidrosis Now Furthermore, also manufacture turning Japan country RX axillary treatment it's Japanese gel under first-in-class the is for to indication. launching of in name brand This later first Kaken and regulatory approval ECCLOCK now the fully Pharmaceutical. sofpironium partner axillary of Japan to is is bromide X% bromide Japan, they past focused to for year. approve sofpironium and be development treatment in received any in Kaken note, this primary hyperhidrosis. Japan the therapy on sofpironium topical Important product ECCLOCK market our marketed a
of to percentage royalties sofpironium could value over Brickell net As years a Japan. represent sales is to based in as of reminder, gel well significant on based tiered Brickell the a bromide sales This to payments entitled milestone receive come. as
patent provide of forms Japanese protection Importantly, expected a or to matter directed together is sofpironium the with and of with claims patent crystalline through Japan XXXX. forms that composition office, Kaken, additional to polymorphic, bromide granted these the for we by in novel distinct developed were newly
prosecuting are matter on actively subject basis. patents to global related a this We
into us agreement proprietary collaboration DNA with develop Lastly, plasmid we vaccine to AnGes, a with entered rights certain provides COVID-XX. intended which prevent adjuvanted investigational to their
first Our Japan is studies The clinical candidate quarter rights the X guide from with these studies results U.S., through South development certain will AnGes data of vaccine candidate. vaccine our Phase Phase decision this novel other markets. readouts include its efforts any in X America emerging and with expected conducting and the around potential XXXX.
let's Deepak Deepak? studies. our Cardigan X to it and Now discuss over X X Phase turn to Cardigan
